Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 8/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260774 | 0.87 | ADORA1 (0.77) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL4825271 | 0.84 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL24859012 | 0.84 | ADORA1 (0.94) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4825106 | 0.83 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL4822464 | 0.83 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL4824825 | 0.83 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL2754553 | 0.83 | KMT2A (1.00) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL4827120 | 0.81 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL24859034 | 0.80 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4829224 | 0.80 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449470-B2 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2008-11-11 | — | — | US | claimed |
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2007-02-08 | — | — | US | claimed |
| EP-1667985-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | Universiteit Leiden (NL) | 2006-06-14 | — | — | EP | claimed |
| WO-2005033084-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | UNIVERSITEIT LEIDEN (NL) | 2005-04-14 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-7449470-B2 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2008-11-11 | — | — | US | disclosed |
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2007-02-08 | — | — | US | disclosed |
| EP-1667985-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | Universiteit Leiden (NL) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005033084-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | UNIVERSITEIT LEIDEN (NL) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.